BLT Announces Health Canada approval for BLIS M18 Probiotic

Blis Technologies Announces Health
Canada approval for BLIS M18™
Probiotic
Blis Technologies announces Health Canada approval of BLIS M18
™
probiotic for
use in Health Products with specific and substantial claims.
After reviewing supporting science and safety publications, Health Canada has
approved products containing BLIS M18
™
to include claims such as, “promotes oral
health [through the re-colonisation of the oral cavity]”, “helps decrease build-up of
dental plaque”, “helps prevent gingivitis and plaque build-up in conjunction with good
oral hygiene”, “aids in gum healing”.
Brian Watson, CEO of Blis Technologies, said we have had a push on obtaining
regulatory approvals in key markets and this is another success from this effort
which can have long lead times. “These regulatory approvals provide access to new
markets with Canada representing an attractive target for future sales. We now have
both BLIS K12
™
and BLIS M18
™
approved in Canada with substantial label claims
and we will be accelerating our sales plans for this attractive market”.
For further comment contact:

Brian Watson
Chief Executive Officer
027 705 9133







About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining
innovation with evidence-based research and the highest quality production controls enables the delivery
of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune
support and teeth and gum health. BLIS products are sold throughout New Zealand and in Australia, Asia,
Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz.